Document Detail


A new pulsed electric field therapy for melanoma disrupts the tumor's blood supply and causes complete remission without recurrence.
MedLine Citation:
PMID:  19408306     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
We have discovered a new, ultrafast therapy for treating skin cancer that is extremely effective with a total electric field exposure time of only 180 microsec. The application of 300 high-voltage (40 kV/cm), ultrashort (300 nsec) electrical pulses to murine melanomas in vivo triggers both necrosis and apoptosis, resulting in complete tumor remission within an average of 47 days in the 17 animals treated. None of these melanomas recurred during a 4-month period after the initial melanoma had disappeared. These pulses generate small, long-lasting, rectifying nanopores in the plasma membrane of exposed cells, resulting in increased membrane permeability to small molecules and ions, as well as an increase in intracellular Ca(2+), DNA fragmentation, disruption of the tumor's blood supply and the initiation of apoptosis. Apoptosis was indicated by a 3-fold increase in Bad labeling and a 72% decrease in Bcl-2 labeling. In addition, microvessel density within the treated tumors fell by 93%. This new therapy utilizing nanosecond pulsed electric fields has the advantages of highly localized targeting of tumor cells and a total exposure time of only 180 microsec. These pulses penetrate into the interior of every tumor cell and initiate DNA fragmentation and apoptosis while at the same time reducing blood flow to the tumor. This new physical tumor therapy is drug free, highly localized, uses low energy, has no significant side effects and results in very little scarring.
Authors:
Richard Nuccitelli; Xinhua Chen; Andrei G Pakhomov; Wallace H Baldwin; Saleh Sheikh; Jennifer L Pomicter; Wei Ren; Christopher Osgood; R James Swanson; Juergen F Kolb; Stephen J Beebe; Karl H Schoenbach
Related Documents :
11481276 - Exudative retinal detachment from malignant uveal melanoma: predictors and prognostic s...
19737966 - Leukotriene b4 creates a favorable microenvironment for murine melanoma growth.
8746776 - Phosphorothioate oligonucleotides reduce melanoma growth in a scid-hu mouse model by a ...
12485936 - Mac-1 (cd11b/cd18) is crucial for effective fc receptor-mediated immunity to melanoma.
16146636 - Inhibition of shc/grb2 protein-protein interaction suppresses growth of b104-1-1 tumors...
8956456 - Tumors derived from antigen presenting cells.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.    
Journal Detail:
Title:  International journal of cancer. Journal international du cancer     Volume:  125     ISSN:  1097-0215     ISO Abbreviation:  Int. J. Cancer     Publication Date:  2009 Jul 
Date Detail:
Created Date:  2009-06-01     Completed Date:  2009-06-19     Revised Date:  2011-08-01    
Medline Journal Info:
Nlm Unique ID:  0042124     Medline TA:  Int J Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  438-45     Citation Subset:  IM    
Copyright Information:
Copyright 2009 UICC.
Affiliation:
Frank Reidy Research Center for Bioelectrics, Old Dominion University, Norfolk, VA 23510, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Animals
Calcium / metabolism
Electric Stimulation Therapy*
Female
Immunohistochemistry
Melanoma, Experimental / blood supply,  therapy*
Mice
Mice, Nude
Patch-Clamp Techniques
Recurrence
Remission Induction
Skin Neoplasms / blood supply,  metabolism,  therapy*
Grant Support
ID/Acronym/Agency:
R43 CA123924-01A2/CA/NCI NIH HHS; R44 CA117227-03/CA/NCI NIH HHS; R44 CA123924-03/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
7440-70-2/Calcium
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Downregulation of the c-MYC target gene, peroxiredoxin III, contributes to arsenic trioxide-induced ...
Next Document:  IgE, allergy, and risk of glioma: update from the San Francisco Bay Area Adult Glioma Study in the t...